KIT overexpression induces proliferation in astrocytes in an imatinib‐responsive manner and associates with proliferation index in gliomas

Activating gene mutations, gene amplifications and overexpressed proteins may be useful as targets for novel therapies. Alterations at chromosome locus 4q12 are associated with gliomas and the region harbors the receptor tyrosine kinase gene KIT, which is frequently amplified in gliomas, and also overexpressed in a subset of gliomas. KIT and its ligand stem cell factor are widely expressed in embryonic and adult mouse brain, and they play a role in many signal transduction pathways involved in cellular proliferation, differentiation and cancer cell metastasis. However, the function of KIT in gliomagenesis or disease progression remains unresolved as well as its role in neural and brain tumor development. In this study, we utilized lentivirus‐mediated gene transfer to deliver the KIT gene into mouse astrocytes. The growth properties of KIT overexpressing cells were analyzed using several in vitro functional assays. The effect of receptor tyrosine kinase inhibitor imatinib on astrocyte growth was also investigated. Our results indicate that overexpression of KIT in mouse astrocytes promotes cell proliferation, and the increased proliferation is partly inhibited by imatinib treatment. Furthermore, KIT overexpression induces phenotypic changes in the cells suggesting that KIT may play a role in astrocyte growth regulation. © 2008 Wiley‐Liss, Inc.

[1]  J. Reis-Filho,et al.  Molecular Alterations of KIT Oncogene in Gliomas , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[2]  A. Paetau,et al.  Amplification of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas , 2006, Molecular Cancer Research.

[3]  C. Heldin,et al.  Characterization of an imatinib-sensitive subset of high-grade human glioma cultures , 2006, Oncogene.

[4]  J. Isola,et al.  Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival , 2006, Neuropathology and applied neurobiology.

[5]  A. Paetau,et al.  Molecular genetic analysis of the REST/NRSF gene in nervous system tumors , 2006, Acta Neuropathologica.

[6]  A. Buschauer,et al.  Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity , 2006, Journal of Cancer Research and Clinical Oncology.

[7]  Jayant P. Menon,et al.  Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. , 2006, Cancer cell.

[8]  L. Reber,et al.  Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. , 2006, European journal of pharmacology.

[9]  Allan H Friedman,et al.  Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Dresemann Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  H. Joensuu,et al.  Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme , 2005, The Journal of pathology.

[12]  Robin L. Jones,et al.  The development and application of imatinib , 2005, Expert opinion on drug safety.

[13]  K. Forsberg-Nilsson,et al.  Stem cell factor is a chemoattractant and a survival factor for CNS stem cells. , 2004, Experimental cell research.

[14]  K. Jin,et al.  Stem cell factor stimulates neurogenesis in vitro and in vivo. , 2002, The Journal of clinical investigation.

[15]  Eric C. Holland,et al.  Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice , 2000, Nature Genetics.

[16]  J. Tonn,et al.  Matrix metalloproteinases and their biological function in human gliomas , 1999, International Journal of Developmental Neuroscience.

[17]  Hannu,et al.  Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. , 1993, The American journal of pathology.

[18]  K. Manova,et al.  c-kit receptor and ligand expression in postnatal development of the mouse cerebellum suggests a function for c-kit in inhibitory interneurons , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[19]  N. Copeland,et al.  Embryonic RNA expression patterns of the c‐kit receptor and its cognate ligand suggest multiple functional roles in mouse development. , 1991, The EMBO journal.

[20]  K. Franssila,et al.  KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Welte,et al.  Coexpression of stem cell factor and its receptor c-Kit in human malignant glioma cell lines , 2004, Acta Neuropathologica.

[22]  Su-Chun Zhang,et al.  Cellular localization of stem cell factor and c‐kit receptor in the mouse nervous system , 1997, Journal of neuroscience research.